SPDR S&P Biotech ETF (XBI) Stock Price, News, Quotes-Moomoo

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Novo Nordisk, Eli Lilly Could Face Downward Pressure Despite Market Dominance From Potentially 16 New Obesity Drugs: See The Names
Benzinga14:11 ET
Cantor Fitzgerald Reiterates Neutral on Alnylam Pharmaceuticals, Maintains $220 Price Target
Benzinga13:12 ET · Ratings
Capricor Reports Positive Long-term Data for DMD Drug Deramiocel
Seeking Alpha12:41 ET
$1000 Invested In Alnylam Pharmaceuticals 20 Years Ago Would Be Worth This Much Today
Benzinga12:00 ET
Capitulation in Biotech Is Near, as Well as a Rally – Piper Sandler
Seeking AlphaOct 11 11:17 ET
Dividend Roundup: Pfizer, Caterpillar, PNC Financial, AbbVie, and More
Seeking AlphaOct 11 08:29 ET

Comments

Bellaah

Sep 11 11:10

$SPDR S&P Biotech ETF (XBI.US)$ 95

1

Moomoo Learn

Sep 6 03:05

Columns Navigating the wave of lower interest rates

Given the strong market expectations for a Federal Reserve rate cut, as indicated by the CME data with a 57% chance for a 25-basis-point reduction and a 43% chance for a 50-basis-point cut in September, investors are poised to reconsider their strategies.
With the Fed's September meeting likely to deliver a rate decrease, the question arises: how should investors allocate assets during an interest rate cut cycle? Let's delve into the tactics and consid...

+1

CPI hits 3-year low: How will it sway the Fed rate decision?

15

3

frankinglily

Aug 25 22:03

Argument:
The upcoming interest rate cuts are poised to benefit the biotech stock industry, setting the stage for strong performance in the coming quarters.
Reasons:
Cheaper Funding: Lower interest rates make it easier for biotech companies to access capital for research and development, accelerating their progress and growth potential.
Attractive Valuations: Biotech stocks are currently trading at attractive levels, offering investors an opportunity to capitalize on the sector's long-term pot...

Powell said it's time to cut: Will the market go wild?

5

1

Meltyy

Aug 6 02:51

$XBI down 3% today and 5% since before last Friday’s jobs report.

$SPDR S&P Biotech ETF (XBI.US)$
» Is this a smid-cap biopharma buying opportunity? 🤔
Stock market sell-off, e.g., $NASDAQ, started late last week on weak jobs data
XBI/smid-cap biopharma were part of sell-off
But..
» Is this sell-off justified for smid-cap biopharma?
» Is this a buying opportunity for smid-cap biopharma?
💡 Lower economic/jobs data = more likely entering lowering interest rate cycle for Fed Reserve
Usually go...

1

Goodjobguys

Aug 1 09:43

7 Cheap But Risky Biotech Stocks? Funds moving from big corporations to Small Caps?

$Immuneering (IMRX.US)$ $SPDR S&P Biotech ETF (XBI.US)$ $iShares Biotechnology ETF (IBB.US)$ $S&P 500 Index (.SPX.US)$ $BioAtla (BCAB.US)$ $Gilead Sciences (GILD.US)$ $Affimed NV (AFMD.US)$ $Instil Bio (TIL.US)$ $Nkarta (NKTX.US)$
Biotech stocks remain depressed, nearly two years into a dip that has seen the SPDR S&P Biotech ETF XBI 0.05% drop nearly 50%.
The other most-watched exchange-traded fund that tracks the biotech secto...

10

1

XBI SPDR S&P Biotech ETF

Trade Overview

Capital Trend

News

Comments